The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?
Open accessAbstract
OBJECTIVE: An important prognostic factor in any form of infection seems to be glucose control in patients with type 2 diabetes. There is no information about the effects of tight glycemic control on coronavirus disease 2019 (COVID-19) outcomes in patients with hyperglycemia. Therefore, we examined the effects of optimal glycemic control in patients with hyperglycemia affected by COVID-19. RESEARCH DESIGN AND METHODS: Fifty-nine patients with COVID-19 hospitalized with moderate disease were evaluated. On the basis of admission glycemia >7.77 mmol/L, patients were divided into hyperglycemic and normoglycemic groups. Interleukin 6 (IL-6) and D-dimer levels were evaluated at admission and weekly during hospitalization. The composite end point was severe disease, admission to an intensive care unit, use of mechanical ventilation, or death. RESULTS: Thirty-four (57.6%) patients were normoglycemic and 25 (42.4%) were hyperglycemic. In the hyperglycemic group, 7 (28%) and 18 (72%) patients were diagnosed with diabetes already before admission, and 10 (40%) and 15 (60%) were treated without and with insulin infusion, respectively. The mean of glycemia during hospitalization was 10.65 ± 0.84 mmol/L in the no insulin infusion group and 7.69 ± 1.85 mmol/L in the insulin infusion group. At baseline, IL-6 and D-dimer levels were significantly higher in the hyperglycemic group than in the normoglycemic group (P < 0.001). Even though all patients were on standard treatment for COVID-19 infection, IL-6 and D-dimer levels persisted higher in patients with hyperglycemia during hospitalization. In a risk-adjusted Cox regression analysis, both patients with hyperglycemia and patients with diabetes had a higher risk of severe disease than those without diabetes and with normoglycemia. Cox regression analysis evidenced that patients with hyperglycemia treated with insulin infusion had a lower risk of severe disease than patients without insulin infusion. CONCLUSIONS: Insulin infusion may be an effective method for achieving glycemic targets and improving outcomes in patients with COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14817 · Cited by 3,559
Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961 · cited 1×
“Indeed, our group demonstrated that healthy subjects and patients with impaired glucose tolerance have inflammatory cytokines interleukin (IL) 6, tumor necrosis factor-a (5), and D-dimer (6) overproduction following the appearance of hyperglycemia.”
BackgroundSelf-citationChannappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,419
Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19
Gao, Y., Li, T., Han, M., Li, X., Wu, D., Xu, Y., Zhu, Y., Liu, Y., Wang, X., & Wang, L. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25770 · Cited by 1,047
2019 Novel coronavirus: where we are and what we know
Cheng, Z. J., & Shan, J. (2020) · Infection · doi:10.1007/s15010-020-01401-y · Cited by 629
Nieuwdorp, M., van Haeften, T. W., Gouverneur, M. C. L. G., Mooij, H. L., van Lieshout, M. H. P., Levi, M., Meijers, J. C. M., Holleman, F., Hoekstra, J. B. L., Vink, H., et al. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1103 · Cited by 620
Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome
Hendren, N. S., Drazner, M. H., Bozkurt, B., & Cooper, L. T. (2020) · Circulation · doi:10.1161/circulationaha.120.047349 · Cited by 576
Cited by
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
COVID-19 in people with diabetes: understanding the reasons for worse outcomes
Apicella, M., Campopiano, M. C., Mantuano, M., Mazoni, L., Coppelli, A., & Del Prato, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30238-2 · Cited by 903
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection
Montefusco, L., Ben Nasr, M., D’Addio, F., Loretelli, C., Rossi, A., Pastore, I., Daniele, G., Abdelsalam, A., Maestroni, A., Dell’Acqua, M., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00407-6 · Cited by 423
Zhang, L.-K., Sun, Y., Zeng, H., Wang, Q., Jiang, X., Shang, W.-J., Wu, Y., Li, S., Zhang, Y.-L., Hao, Z.-N., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-00235-0 · Cited by 298
Metadata
- Authors
- Sardu, C., D’Onofrio, N., Balestrieri, M. L., Barbieri, M., Rizzo, M. R., Messina, V., Maggi, P., Coppola, N., Paolisso, G., & Marfella, R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-05-19
- Volume
- 43
- Issue
- 7
- Pages
- 1408-1415
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3025089998
- Cited by
- 424
- References
- 23
- FWCI
- 59.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- PRIN 2017 (2017FM74HK_002)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? https://app.cochat.ai/papers/10.2337/dc20-0723
- The paper
- Sardu, C., D’Onofrio, N., Balestrieri, M. L., Barbieri, M., Rizzo, M. R., Messina, V., Maggi, P., Coppola, N., Paolisso, G., & Marfella, R. (2020). Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care. https://doi.org/10.2337/dc20-0723
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.